Outlook Therapeutics
Iselin
About Outlook Therapeutics
Outlook Therapeutics develops an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. Their ophthalmic formulations also use in treating retinal diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $376.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:OTLK
- Website: outlooktherapeutics.com
- Phone: +1 609 619 3990
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/outlook-therapeutics-50032 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.